First day of new stock | Eastroc Beverage (09980) debuts on the market, opening flat in the morning. The company has been ranked first in the Chinese functional beverage market for four consecutive years.
Dongpeng Beverage (09980) made its debut on the stock market, with an IPO price of HKD 248 per share. A total of 40,889,900 shares were issued, with a net proceeds of approximately HKD 9.994 billion. As of the time of this report, there has been no change in the stock price, which remains at HKD 248, with a trading volume of HKD 4.2 billion.
Eastroc Beverage (09980) will be listed for the first time, with an offering price of 248 Hong Kong dollars per share and a total issuance of 40,889,900 shares, in lots of 100 shares each, with a net proceeds of approximately 9.994 billion Hong Kong dollars. As of the time of writing, there has been no change in the price, which remains at 248 Hong Kong dollars, with a trading volume of 420 million Hong Kong dollars.
According to public information, Eastroc Beverage is the leading functional beverage company in China, with its revenue growth ranking first among the top 20 listed soft drink companies globally. According to a report by Frost & Sullivan, the company has been ranked as the top functional beverage company in China by sales volume for four consecutive years starting from 2021, with its market share increasing from 15.0% in 2021 to 26.3% in 2024. In terms of retail sales, the company is the second largest functional beverage company in 2024, with a market share of 23%.
The company has established a nationwide three-dimensional sales network, covering over 4.3 million terminal sales outlets as of September 30, 2025, achieving nearly 100% coverage of prefecture-level cities in China. The sales team works closely with distribution partners to continuously improve product market penetration and optimize product display for increased visibility and penetration rates. The company continues to expand its omni-channel sales network to meet consumers' daily consumption needs in various scenarios.
Related Articles

HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) continues to rise by over 10%, with an expected increase in net profit of up to 4.4 times for the full year. The company has also achieved multiple major external authorizations.

HK Stock Market Move | XPENG-W(09868) continues to fall by more than 3%, with a 34.07% year-on-year decrease in new car deliveries in January.

HK Stock Market Move | Knowledge Atlas (02513) rose by more than 7% in early trading, announcing the official release and open sourcing of GLM-OCR. It is reported that they plan to launch GLM-5 in the next two weeks.
HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) continues to rise by over 10%, with an expected increase in net profit of up to 4.4 times for the full year. The company has also achieved multiple major external authorizations.

HK Stock Market Move | XPENG-W(09868) continues to fall by more than 3%, with a 34.07% year-on-year decrease in new car deliveries in January.

HK Stock Market Move | Knowledge Atlas (02513) rose by more than 7% in early trading, announcing the official release and open sourcing of GLM-OCR. It is reported that they plan to launch GLM-5 in the next two weeks.

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


